BioCentury
ARTICLE | Financial News

Alcobra files for IPO

January 16, 2013 2:28 AM UTC

Alcobra Ltd. (Tel Aviv, Israel) proposed to raise up to $17.3 million in an IPO on NASDAQ underwritten by Aegis Capital. Alcobra's lead compound is MG01CI, an extended-release formulation of metadoxine that met the primary endpoint in a Phase II trial to treat adult ADHD. The company said it plans to meet with U.S. and EU regulatory agencies in the next six months to discuss further clinical trials for the product (see BioCentury Extra, Sept. 7, 2011). ...